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DOI 10.1186/s12955-014-0200-6RESEARCH Open AccessDo chronic disease patients value generic health
states differently from individuals with no chronic
disease? A case of a multicultural Asian population
Mihir Gandhi1,2,3*, Julian Thumboo4,5, Nan Luo6, Hwee-Lin Wee7 and Yin-Bun Cheung2,3Abstract
Background: There is conflicting evidence as to whether patients with chronic disease value hypothetical health
states differently from individuals who have not experienced any long-lasting diseases. Furthermore, most studies
regarding this issue have been conducted in western countries, with only one conducted in Asia. We aimed to
evaluate possible systematic differences in the valuation of EuroQol Group five dimensions 3-level (EQ-5D-3L) health
states by chronic disease patients and a population with no chronic disease in Singapore.
Methods: A face-to-face survey for the valuation of the 42 health states of the EQ-5D-3L using the visual analogue
scale (VAS) method was conducted in Singapore. The survey also asked participants to report any chronic diseases
they had. Ordinary least-square regression models were employed to assess possible differences in the valuation
scores of all health states, severe health states and non-severe health states by individual chronic disease patient
groups (diabetes, rheumatism, hypertension, heart diseases and lung diseases) and by a group of participants with
no chronic disease. A difference of 4 to 8 points on the 100-point VAS was considered to be of practical significance.
Results: The analysis included 332 participants with at least one chronic disease and 651 participants with no chronic
disease. After taking health state descriptors and covariates into account, mean valuation scores of the 42 health states
by the heart disease group were higher by 4.6 points (p-value = 0.032) compared to the no chronic disease group.
Specifically, the heart disease group valued severe health states 5.4 points higher (p-value = 0.025) than the no chronic
disease group. There was no practically significant difference in the mean valuation score of non-severe health states
between the heart disease group and the no chronic disease group. No practically significant differences were found in
the mean valuation score of all health states, severe health states and non-severe health states between any other
chronic disease group and the no chronic disease group.
Conclusions: In Singapore, heart disease patients valued EQ-5D-3L severe health states differently from individuals with
no chronic disease. Other chronic disease groups did not value EQ-5D-3L health states differently from the no chronic
disease group.
Keywords: Chronic disease, EQ-5D, Utility, ValuationBackground
There is conflicting evidence as to whether patients with
chronic disease value their own health states differently
from individuals who have not experienced any such dis-
eases [1,2]. Similar conflicting results have been reported
for how patients with chronic disease and individuals with* Correspondence: mihir.gandhi@scri.edu.sg
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unless otherwise stated.no such disease experience value hypothetical health states
[1,2]. The difference in valuation of health states between
the patients and individuals with no disease experience
may arise because the patients might have adapted to their
condition or because individuals with no disease experi-
ence overestimate the impact of disease or disability on
quality of life [3]. Most studies that have evaluated differ-
ences in valuations by these two groups have been con-
ducted in western countries; only one study has reported
on an Asian population [1,4]. This is important as there is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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different countries regarding the valuation of health states
[5,6]. In addition, most of the studies that have compared
the valuation by chronic disease patients and that of by
a no chronic disease population have compared the
valuation of only selected disease-related health states,
without covering a range of mild to severe states. Only
a few studies have investigated the potential systemic
difference between valuation by specific chronic disease
patients and individuals with no experience of chronic
disease regarding health states with a wide range of se-
verity [7,8].
Differences in valuation between chronic disease patients
and individual with no chronic disease may affect the out-
comes of analyses of healthcare interventions. Cost-utility
analysis (CUA) is a cost-effectiveness analysis in which the
effect of health-care interventions is measured in terms of
quality-adjusted life-years (QALYs) gained. QALYs are esti-
mated as the time spent in a health state (quantity of life)
multiplied by its utility (quality of life). QALYs are also an
important outcome for monitoring health status in individ-
ual patients, measuring population health and measuring
the impact of health-care intervention in clinical studies
[9]. The question of whose utility (general-population-
derived or patient-derived) should be used in clinical
decision making and economic evaluations of health-care
interventions has been debated in the literature [10,11].
The answer depends on the purpose for which the util-
ity is used and context in which it is used. A general
population-derived utility is desirable when the utility
is needed to inform decisions that allocate societal re-
sources, while a patient-derived utility may be more appro-
priate when making treatment decisions guided by patient
preferences. The Panel on Cost-Effectiveness in Health and
Medicine in the United States and the National Institute
for Health and Care Excellence in England and Wales
recommend that a general-population-derived utility for
health states be used for cost-effectiveness analyses [12,13].
However, the latest systematic review revealed that less than
one-third of published CUAs use a general-population-
derived utility; the remainder used a patient-derived utility, a
clinician- or expert-derived utility, or authors’ judgments
[14]. Many investigators use a patient-derived utility because
they believe that patients who have experienced the disease
conditions can appraise their conditions more accurately
than individuals who have not experienced such conditions
[15]. On the other hand, CUAs using a general population-
derived utility can help broader system-level decision
making to prioritize health care funding in order to
maximize the benefit for patients with different medical
conditions- considering patients’ as well as non-patients’
perspectives [11]. This is a recommended approach when
the health care is funded by the public/tax payers. How-
ever, if the health care costs are mostly paid by patientsthemselves, patient-derived utility should be considered.
In Singapore, more than 60% of the health care costs are
borne by patients [16]; and therefore patient-derived utility
is relevant.
Utilities of health states from generic quality of life in-
struments, such as the EuroQoL Group five dimensions
(EQ-5D) or Short Form six dimension (SF-6D), are pre-
ferred over health states from disease-specific quality of
life instrument for CUAs. Utilities of generic health states
allow comparisons of the effects on quality of life of different
health-care interventions in different diseases. Currently, the
EQ-5D is the most commonly used generic instrument for
CUAs [14].
The present study draws on data from a valuation
study of EQ-5D 3-level (EQ-5D-3L) health states in the
Singapore general population which involves self-reporting
of chronic diseases. We aimed to explore whether there
are systematic differences in values for health states elicited
by specific chronic disease patients (CDP) and by the no
chronic disease population (NCDP). We also explored
how the most severe health state and unconscious state
were valued in relation to dead state by specific CDP
and NCDP.
Methods
Valuation survey procedures
In 2009, the EQ-5D-3L—using the visual analogue scale
(VAS) method—was used to conduct a cross-sectional,
face-to-face survey of health state valuation in a repre-
sentative sample of 1034 participants from the general
population of Singapore. Singapore is a multi-ethnic city
state with a rapidly increasing aging population. Its popula-
tion is 75% Chinese, 13% Malay, 9% Indian (mostly Tamil
speaking) and 3% others [17]. A multi-stage sampling
approach was used to randomly select residential blocks,
within which households were selected. We interviewed
potential participants (one per household) who satisfied
the pre-set recruitment quotas for ethnicity (400 Chinese,
400 Malay, and 234 Indians), gender (50% Female) and
age (30% of 21–34 years, 40% of 35–49 years, and 30% of
50+ years). Within each ethnicity, there was a quota that
half of the participants would use English for the interview
and the remaining half would use their native language
(i.e., Mandarin for Chinese, Malay for Malays and Tamil
for Indians).
The EQ-5D-3L consists of 5 dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression) with 3 response levels for each dimension
(1: no problems, 2: some problems, and 3: extreme
problems). This instrument thus describes 243 health
states. Each health state is represented by one response
level from each of the 5 dimensions. For example, 11112
describes a health state with no problems on the first 4 di-
mensions and some problem related to anxiety/depression.
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protocol of Dolan [18]. Immediate death and the most se-
vere state (‘33333’) were labeled as ‘dead’ and ‘all-worst’, re-
spectively. Each participant was asked to compare between
‘dying now’ and ‘living for the rest of his/her life in all-
worst’, from which the less desirable state was assigned a
value 0 on the VAS. Each participant was then asked to
value a unique set of 6 states from the subset of EQ-5D-3L
states and either ‘dead’ or the ‘all-worst’ state, whichever
one was not valued earlier at 0. The unique set of 6 health
states that was assigned to each participant included states
that were spread widely over the valuation space. A 100-
point “feeling thermometer” with endpoints of 100 (most
desirable, i.e., perfect health) and 0 (least desirable) was
used as aVAS. For the six assigned states, participants were
required to indicate where they would rate each of the
states on the “feeling thermometer” by imagining them-
selves in that state for the rest of their life without chan-
ging. The participants were allowed to value more than
one health state at the same level of VAS. In addition to
the six assigned states, ‘unconscious’ state was also valued.
Participants were also asked to report their chronic
diseases. The list of chronic diseases included diabetes,
high blood pressure (hypertension), heart diseases, stroke,
asthma or other lung diseases, cancer, rheumatism/back
pain or other bone or muscle illness, mental illness (e.g.,
depression, anxiety neurosis, schizophrenia) and other ill-
ness (e.g., kidney problems or dialysis).
This study was approved by the SingHealth Central-
ized Institutional Review Board.
Analyses
The analysis included participants with diabetes, high
blood pressure/hypertension, heart diseases, asthma/lung
diseases, rheumatism/back pain/other bone-muscle illness,
or no chronic disease. The number of participants with
other chronic diseases was small (<10) and these partici-
pants were not included in the analyses described in this
manuscript.
Participants who met the following criteria were ex-
cluded from our analysis: a) valued less than 3 health
states, b) did not value ‘dead’ or ‘all-worst’ state, c) valued
‘dead’ or ‘all-worst’ or ‘unconscious’ state higher than all of
the other states, d) gave the same valuation score to all the
health states, e) self-reported or rated by the interviewers
as having a poor understanding of the health states de-
scription or valuation tasks. The valuation score used in
the analyses was ‘raw’ VAS valuation score, which ranged
from 0 (worst possible score) to 100 (best possible score).
There is no consensus among researchers or regulatory
bodies regarding the optimal method of transforming the
valuation scores into utility [19].
We performed a separate analysis to compare the val-
uations by participants in each of the CDP groups withthose of the NCDP group. Each analysis included two
ordinary least-square regression models. Model I was
used for the comparison of overall difference in valu-
ation scores (including all the health states) between
each CDP group and the NCDP group. Model II was
used for the comparison of the differences in valuation
scores of non-severe health states and severe health
states by including an interaction term between the in-
dicator variable for severe health state (versus non-severe
health state) and the indicator variable for the specific
CDP group (versus the NCDP group). We considered
health states with at least one dimension at level 3 as
“severe” health states, and the remaining states as “non-
severe”.
Model I was performed for the valuation score with an
indicator variable representing a specific CDP group, the
members of which might have co-morbid conditions,
versus the NCDP group as the independent variable. The
model adjusted for indicator variables that represented the
level of severity in each dimension of the health states.
That is, including 2 indicator variables for each of the 5 di-
mensions of EQ-5D-3L. Furthermore, we included an in-
dicator variable (commonly called ‘N3’ in the cost-utility
analysis literature) to take into account additional disutil-
ities when a severe problem (level 3) was reported on at
least one dimension [20]. Finally, the comparison adjusted
for ethnicity, gender, age, marital status, education level,
religion and house type because the CDP group being ana-
lyzed and NCDP group might differ in these background
characteristics.
Model II further included an interaction term between
the CDP group indicator and the N3 in Model I. In this
model, the coefficient of the CDP group provides an es-
timate of the difference between valuation scores of non-
severe health states; whereas its sum with the interaction
term provides an estimate of the difference between
valuation scores of severe health states by the specific
CDP group and the NCDP group after taking the health
state descriptors and participants’ background character-
istics into account. Perfect health state, ‘unconscious’
state and ‘dead’ state were excluded from Models I and II.
The perfect health state was assigned a valuation score of
100 for each participant. Since each of the participants
valued 6 health states, we used the Eicker-Huber-White
robust standard error for cluster data for statistical in-
ference [21].
We compared the valuation of the ‘all-worst’ and
‘unconscious’ health states with the valuation of ‘dead’
state by each of the CDP groups and the NCDP group.
The mean valuation scores of the ‘all-worst’ state and
‘unconscious’ state were compared with the ‘dead’ state
using a paired t-test.
All the analyses were carried out using Stata/MP 10.1
for Windows. A minimally important difference of 4 to
Gandhi et al. Health and Quality of Life Outcomes  (2015) 13:8 Page 4 of 98 points on the 100-point VAS was considered to be of
practical significance [22-24].
Results
All 1034 participants provided demographic and health char-
acteristic information. Nine participants had chronic diseases
other than diabetes, high blood pressure/hypertension, heart
disease, asthma/lung disease or rheumatism/back pain/other
bone-muscle illness. Thirty-four participants valued ‘dead’
state higher than all the other states, 3 participants valued
‘unconscious’ state higher than all the other states, 1
participant did not value the ‘all-worst’ state and 4
participants were observed to have a poor understand-
ing of valuation tasks. Hence, a total of 51 participants
were excluded from the analysis. Table 1 shows the
demographic and health characteristics of the 983 partici-
pants that were included in the analysis. The percentage
of participants who had good-to-excellent self-reported
general health varied between 68% and 75% among the
CDP groups (Diabetes: 70/102, Rheumatism: 122/162,
Hypertension: 107/145, Heart diseases: 29/44, Lung dis-
eases: 30/44) as compared to 95% among NCDP group
(621/651). Participants in the CDP groups were older,
had lower education level and lower self-reported general
health compared to participants in the NCDP group.
Table 2 summarizes the comparison of health state
valuation scores between the CDP groups and the NCDP
group. Mean observed differences between the CDP groups
and the NCDP group regarding the valuation score of all
the 42 EQ-5D health states, non-severe health states and
severe health states ranged from −3.3 to 0.5, −3.7 to −1.0
and −2.8 to 2.1, respectively. After taking health state de-
scriptors and covariates into account in the regression ana-
lysis, the mean differences between the CDP groups and
the NCDP group regarding valuation scores of all the
health states ranged from −2.5 to 1.6 (each p-value >0.05),
except for the heart disease group. The adjusted mean valu-
ation score of all the health states for the heart disease
group was 4.6 points higher (95% CI: 0.4 to 8.9; p-value =
0.032) than that of the NCDP group. Similarly, after taking
health state descriptors and covariates into account, the
mean differences between the CDP group and the NCDP
group regarding severe health state valuation scores ranged
from −2.4 to 1.8 (each p-value >0.05), except for the heart
disease group. The adjusted mean valuation score of severe
states for the heart disease group was 5.4 points higher
(95% CI: 0.7 to 10.1; p-value = 0.025) than that of the
NCDP group. After taking health state descriptors and co-
variates into account, there was no practically significant
difference in the mean valuation scores of non-severe
health states between any CDP group and the NCDP
group. The changes in the mean differences after the
adjustment for the covariates could be due to differ-
ences in the distribution of demographic characteristicsbetween the CDP and NCDP groups (please see Table 1).
For example, the NCDP group had more participants mar-
ried/living with partners, which was associated with higher
value, compared with unmarried participants in multi-
variable analysis. After statistical adjustment, the differ-
ence between NCDP and lung disease groups would
become smaller. Similarly, the NCDP group had differ-
ences in multiple demographic characteristics, such as
more female participants, fewer Indian participants, and
more participants following Buddhism/Taoism, which were
associated with higher value, compared to the heart disease
group. Thus, after statistical adjustment, the heart disease
group had higher valuation score compared to the NCDP
group. Other demographic characteristics did not have
much influence on the valuation score (Details not shown).
Table 3 summarizes the comparison of valuation scores
for the ‘all-worst’ state with those of the ‘dead’ state by dis-
ease group. Except for the heart disease group, the mean
difference in valuation scores of ‘all-worst’ state and ‘dead’
state by the CDP groups and the NCDP group were
within the range of −8.4 points (95% CI: −11.8 to −4.9;
p-value < 0.001) to −5.3 points (95% CI: −8.8 to −1.8;
p-value = 0.003). For the heart disease group, this differ-
ence was −2.3 points (95% CI: −7.3 to 2.8; p-value = 0.370).
Table 4 summarizes the comparison of valuation scores
for ‘unconscious’ state with those of the ‘dead’ state by dis-
ease group. Except for the heart disease group, the mean
difference in valuation scores of ‘unconscious’ state and
‘dead’ state by the CDP groups and the NCDP group were
within the range of −0.1 points (95% CI: −3.0 to 2.7;
p-value = 0.922) to 3.0 points (95%CI: −0.1 to 6.0;
p-value = 0.057). For the heart disease group, this differ-
ence was 4.2 points (95% CI: 0.4 to 8.0; p-value = 0.030).Discussion
We examined the potential effect of experience with
chronic disease on the valuation of EQ-5D-3L health
states using the VAS method in a multicultural Asian
population. Valuation by participants with five different
types of chronic disease (diabetes, rheumatism, hyperten-
sion, heart disease and lung disease) was compared with
valuation by participants with no chronic disease.
The heart disease group valued the health states 5 points
higher than did the NCDP group (p-value = 0.032), which
is mainly attributed to the heart participants’ valuation of
the severe health states. This difference was statistically
significant and larger than the minimal important differ-
ence of 4 points for the EQ-5D-3L valuation score, which
indicates that the result is practically meaningful. The
mean differences between the valuation by other CDP
groups (diabetes, rheumatism, hypertension and lung
diseases) and the NCDP group were all smaller than
the minimal important difference.
Table 1 Demographic and health characteristics of the study participants
Characteristics All participants
(N = 983)
No chronic disease
group (N = 651)
Diabetes
(N = 102)
Rheumatism
(N = 162)
Hypertension
(N = 145)
Heart diseases
(N = 44)
Lung diseases
(N = 44)
n (%) n (%) n (%) P-value* n (%) P-value* n (%) P-value* n (%) P-value* n (%) P-value*
Female 493 (50.2) 329 (50.5) 47 (46.1) 0.404 92 (56.8) 0.071 69 (47.6) 0.530 9 (20.5) <0.001 29 (65.9) 0.044
Age (years) <0.001 <0.001 <0.001 <0.001 0.048
21-29 190 (19.3) 168 (25.8) 0 (0.0) 7 (4.3) 2 (1.4) 0 (0.0) 14 (31.8)
30-39 218 (22.2) 178 (27.3) 6 (5.9) 21 (13.0) 7 (4.8) 1 (2.3) 9 (20.5)
40-49 261 (26.6) 181 (27.8) 22 (21.6) 43 (26.5) 24 (16.6) 7 (15.9) 5 (11.4)
50-59 192 (19.5) 91 (14.0) 41 (40.2) 40 (24.7) 57 (39.3) 18 (40.9) 8 (18.2)
60+ 122 (12.4) 33 (5.1) 33 (32.4) 51 (31.5) 55 (37.9) 18 (40.9) 8 (18.2)
Ethnicity 0.001 0.024 0.914 0.001 0.287
Chinese 363 (36.9) 234 (35.9) 26 (25.5) 67 (41.4) 56 (38.6) 9 (20.5) 16 (36.4)
Malay 395 (40.2) 284 (43.6) 37 (36.3) 50 (30.9) 57 (39.3) 14 (31.8) 14 (31.8)
Indian 225 (22.9) 133 (20.4) 39 (38.2) 45 (27.8) 32 (22.1) 21 (47.7) 14 (31.8)
Education level <0.001 <0.001 <0.001 <0.001 0.352
Primary (6 years) or less 187 (19.0) 74 (11.4) 48 (47.1) 60 (37.0) 58 (40.0) 22 (50.0) 12 (27.3)
Secondary (11 years) 555 (56.5) 387 (59.5) 44 (43.1) 79 (48.8) 77 (53.1) 18 (40.9) 22 (50.0)
Diploma/degree or higher 241 (24.5) 190 (29.2) 10 (9.8) 23 (14.2) 10 (6.9) 4 (9.1) 10 (22.7)
Married/living with partner 739 (75.2) 481 (73.9) 84 (82.4) 0.090 128 (79.0) 0.233 120 (82.8) 0.022 38 (86.4) 0.106 23 (52.3) 0.001
Religion 0.051 0.094 0.796 0.017 0.894
Buddhism/Taoism 224 (22.8) 139 (21.4) 19 (18.6) 43 (26.5) 37 (25.5) 4 (9.1) 12 (27.3)
Islam 410 (41.7) 289 (44.4) 41 (40.2) 53 (32.7) 63 (43.5) 17 (38.6) 16 (36.4)
Hinduism/Sikhism 192 (19.5) 117 (18.0) 31 (30.4) 40 (24.7) 24 (16.6) 17 (38.6) 10 (22.7)
Christianity 80 (8.1) 54 (8.3) 7 (6.9) 14 (8.6) 10 (6.9) 3 (6.8) 3 (6.8)
No religion 77 (7.8) 52 (8.0) 4 (3.9) 12 (7.4) 11 (7.6) 3 (6.8) 3 (6.8)
House type 0.377 0.175 0.786 0.204 0.533
Government owned:
4 rooms or smaller
668 (68.0) 449 (69.0) 71 (69.6) 106 (65.4) 96 (66.2) 25 (56.8) 27 (61.4)
Government owned:
5 rooms or bigger
292 (29.7) 191 (29.3) 27 (26.5) 49 (30.3) 45 (31.0) 18 (40.9) 16 (36.4)
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Table 1 Demographic and health characteristics of the study participants (Continued)
Private 23 (2.3) 11 (1.7) 4 (3.9) 7 (4.3) 4 (2.8) 1 (2.3) 1 (2.3)
General health status <0.001 <0.001 <0.001 <0.001 <0.001
Excellent 97 (9.9) 85 (13.1) 3 (2.9) 5 (3.1) 2 (1.4) 2 (4.6) 2 (4.6)
Very good 376 (38.3) 302 (46.4) 19 (18.6) 24 (14.8) 31 (21.4) 6 (13.6) 9 (20.5)
Good 409 (41.6) 234 (35.9) 48 (47.1) 93 (57.4) 74 (51.0) 21 (47.7) 19 (43.2)
Fair 93 (9.5) 30 (4.6) 27 (26.5) 36 (22.2) 32 (22.1) 13 (29.6) 11 (25.0)
Poor 8 (0.8) 0 (0.0) 5 (4.9) 4 (2.5) 6 (4.1) 2 (4.6) 3 (6.8)
*Comparison with the no chronic disease group using Fisher’s exact test.
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Table 2 Comparison of valuation of health states between the chronic disease groups and the no chronic disease
group taking into account health state descriptors and covariates
Health States Diabetes
(n = 102)
Rheumatism
(n = 162)
Hypertension
(n = 145)
Heart diseases
(n = 44)
Lung diseases
(n = 44)
No chronic disease
(n = 651)
All health states1
Mean (SD) 43.6 (30.0) 43.4 (30.6) 44.4 (30.0) 43.1 (28.7) 40.6 (29.5) 43.9 (30.6)
Mean difference (95% CI)2,3 1.6 (−1.2, 4.3) 0.4 (−2.0, 2.8) 0.7 (−1.7, 3.1) 4.6 (0.4, 8.9)* −2.5 (−6.2, 1.2) -
Non-severe health states1,4
Mean (SD) 71.6 (18.8) 71.3 (20.0) 71.2 (19.7) 69.8 (16.8) 69.0 (22.1) 72.7 (19.3)
Mean difference (95% CI)2,3 1.0 (−2.5, 4.6) −0.3 (−3.4, 2.9) −1.0 (−4.3, 2.3) 2.6 (−2.4, 7.6) −2.6 (−9.0, 3.8) -
Severe health states1,4
Mean (SD) 31.4 (25.4) 31.9 (26.6) 33.6 (26.5) 33.7 (26.0) 28.7 (23.6) 31.5 (25.8)
Mean difference (95% CI)2,3 1.8 (−1.2, 4.7) 0.7 (−1.9, 3.3) 1.3 (−1.2, 3.9) 5.4 (0.7, 10.1)* −2.4 (−6.1, 1.2) -
1The study included 42 EQ-5D-3L health states, not including perfect health, unconscious and dead states. The perfect health state of EQ-5D-3L was assigned
default value of 100 points on the visual analogue scale.
2Difference: mean scores of participants with chronic diseases minus mean scores of participants with no chronic disease.
3Using ordinary least square regression model adjusted for health state descriptors, disutility due to severe problems, ethnicity, gender, age, marital status,
education level, religion and house type (see Methods section).
4EQ-5D-3L health states with at least one domain at severity level 3 are considered as ‘severe’ health states. Remaining health states are considered as ‘non-severe’
health states.
*P-value <0.05.
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with all dimensions at extreme severity) was valued worse
than the ‘dead’ state by the majority of participants across
the different types of chronic diseases and the NCDP
group. Except for the heart disease group, all CDP groups
and the NCDP group valued the ‘all worst’ state statisti-
cally and practically significantly lower than the ‘dead’
state. The heart disease group’s valuation of the ‘all-worst’
state was not statistically and practically significantly
different from their valuation of the ‘dead’ state (differ-
ence = −2.3, p-value = 0.370).
We also found that the mean valuation score of the
‘unconscious’ state was likely to be equivalent to the
‘dead’ state by the NCDP group and all of the CDP
groups except for the heart disease group. The difference
in the mean valuation score of the ‘unconscious’ state
and the ‘dead’ state by heart disease group was statisti-
cally significant and higher than the minimal important
difference (difference = 4.2, p-value = 0.030), whereas the
difference was statistically non-significant and less thanTable 3 Comparison of valuation scores between the ‘all-wor
Valuation Scores Diabetes
(n = 102)
Rheumatism
(n = 162)
Hyper
(n = 14
All-worst#
Mean (SD) 3.3 (8.4) 2.1 (6.0) 3
Dead
Mean (SD) 8.6 (13.3) 10.3 (15.9) 11
All-worst - Dead
Mean difference (95% CI) −5.3 (−8.8, −1.8)* −8.1 (−11.0, −5.3)* −8.4 (−
#EQ-5L-3L health state with all its domains at severity level 3 is labelled as ‘all-worst
*P-value < 0.05.4 (minimal important difference) for the diabetes,
rheumatism, hypertension, asthma/lung disease groups
and the NCDP group.
A possible reason for heart disease patients giving higher
valuation scores could be that a higher proportion of heart
disease patients might have experienced one or more
severe heath states, and this might have changed their
perception regarding these health states. This might
not be the case with other CDP groups and the NCDP
group. On the other hand, the majority of CDP groups
and the NCDP group might have experienced the non-
severe health states, thus leading to their similar valuation
of non-severe health states.
Wang et al. [5] in Singapore found that after adjusting
for health state descriptors and demographic characteris-
tics, there was no meaningful difference in the valuation
of severe health states by diabetes patients and a popula-
tion without diabetes. However, the study reported that
diabetes patients valued the non-severe health states 13
points higher than did the no-diabetes population. Ourst’ state and the ‘dead’ state by disease group
tension
5)
Heart diseases
(n = 44)
Lung diseases
(n = 44)
No chronic disease
(n = 651)
.1 (8.6) 4.8 (9.9) 1.7 (5.2) 3.1 (8.3)
.4 (17.1) 7.1 (10.4) 8.5 (10.9) 9.4 (14.1)
11.8, −4.9)* −2.3 (−7.3, 2.8) −6.8 (−10.8, −2.7)* −6.3 (−7.6, −4.9)*
’ health state.
Table 4 Comparison of valuation scores between the ‘unconscious’ state and the ‘dead’ state by disease group
Valuation Scores Diabetes
(n = 102)
Rheumatism
(n = 167)
Hypertension
(n = 147)
Heart diseases
(n = 46)
Lung diseases
(n = 44)
No chronic disease
(n = 667)
Unconscious
Mean (SD) 11.6 (11.1) 10.1 (12.3) 12.0 (13.0) 11.3 (11.7) 10.6 (9.6) 11.8 (12.6)
Dead
Mean (SD) 8.6 (13.3) 10.3 (15.9) 11.4 (17.1) 7.1 (10.4) 8.5 (10.9) 9.4 (14.1)
Unconscious - Dead
Mean difference (95% CI) 3.0 (−0.1, 6.0) −0.1 (−3.0, 2.7) 0.6 (−2.6, 3.8) 4.2 (0.4, 8.0)* 2.1 (−1.4, 5.7) 2.4 (1.2, 3.6)*
*P-value < 0.05.
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noted that Wang et al. included only 3 non-severe health
states; hence their findings have limited applicability.
On the other hand, we used 14 non-severe health states,
which represent more generalized findings.
Our study findings are consistent with those of Pickard
et al. [8]. Using the time trade-off method, Pickard et al.
found no meaningful difference in valuation scores be-
tween CDP (arthritis, diabetes, depression, hay fever,
cancer) and NCDP, except for heart failure patients [8].
Pickard et al. found that after adjusting for covariates, pa-
tients with heart failure only, and patients with heart fail-
ure and at least one other chronic disease, gave valuation
scores higher by 25 points (n = 6, p-value = 0.222) and 7
points (n = 129, p-value = 0.049), respectively, compared
to NCDP.
A possible explanation for no practical differences in the
mean valuation score between individuals with chronic
diseases and individuals without any chronic diseases
might be because in this exercise, individuals with and
without chronic diseases are valuing many hypothetical
health states that are unlikely to reflect the actual health
state(s) that one has experienced. As such, it is probably
not surprising that generally speaking, individuals with
chronic disease might value them similarly to individuals
with no chronic disease.
This study has several potential limitations. First, the
chronic disease conditions were self-reported by the par-
ticipants. We did not collect any further information to
confirm the disease, the severity of the disease or the time
spent with the disease. Hence, there could be a chance of
misclassification regarding reported diseases. A Finnish
study showed that the sensitivity and specificity of self-
reported chronic diseases (diabetes, hypertension, cor-
onary heart disease, asthma and rheumatoid arthritis)
could range from 78% to 96% and 96% to 99%, respectively
[25]. This indicates a relatively large possibility that pa-
tients with chronic diseases could be misclassified into
the NCDP group, but a small possibility that those with
no chronic disease could be misclassified into a chronic
disease group. This should mean that the differencebetween CDP and NCDP might be under-estimated but
not over-estimated. Furthermore, this is a secondary
analysis of existing data. The limited information re-
lated to disease conditions does not allow us to inves-
tigate any concrete reasons for the differences or lack
of differences between the CDP and NCDP. Second,
although our study had a sizable CDP group, nearly
80% of the CDP group self-reported their health status
as good to excellent. Hence, our study findings may
not be generalized to patients at a severe or unstable
stage of chronic disease. Third, our study included only
five chronic diseases (with a relatively small number of
participants) and only one life-threatening chronic disease
(heart diseases). Thus, our study findings may not be
assumed to generalize to other life-threatening chronic
diseases. Fourth, we performed separate statistical tests
for comparing valuation by each CDP group with valu-
ation by the NCDP group without multiplicity adjust-
ment. Furthermore, the sample size was not powered
for this analysis. Thus, the statistically significant find-
ings might be due to inflated Type I error and therefore
require further confirmation. Nevertheless, our findings
are based on a random sample of a chronic disease popu-
lation from the Asian general population. It also in-
cluded many health states with a wide range of severity.
It also has potential to generalize the findings for non-
life-threatening chronic disease patients. We encourage
conducting a larger study that includes a greater variety
of life-threatening chronic disease patients, as well as
varying severity levels and the verification of disease
conditions and severity.Conclusions
Our study findings suggest that heart disease patients value
severe EQ-5D-3L health states differently than individuals
who have no experience with chronic disease when an-
alyzed using the VAS method in a Singaporean popula-
tion. However, the experience of chronic diseases other
than heart disease does not necessarily result in a higher or
lower valuation across all the health states of EQ-5D-3L.
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